VPT:CC - Ventripoint Diagnostics Provides a Corporate Update
(TheNewswire)
Toronto, Ontario – TheNewswire –March 16, 2023 - Ventripoint Diagnostics Ltd.(" Ventripoint " or the " Company "), (TSXV:VPT ) ; ( OTC:VPTDF) is pleased to provide a corporate update on theCompany’s current status and the outlook for 2023.
The Company enters 2023 following an extensive periodof innovation and refinement of its core technology and is nowwell-positioned to capitalize on those investments in creatingawareness and driving market adoption.
Dr. Alvira Macanovic, Ventripoint’s President &CEO stated, “2022 was a transformative year for Ventripoint, and thecompany is in a much stronger position going forward. Ventripointhas gained traction in sales in its key markets and continues momentumas we pursue our mission to improve the lives of patients by providingbetter, simpler, and intelligent tools that give clinicians moreaccurate information and solve their immediate needs. My primary focusnow is to drive revenues as a result of the tactical growth in our salesforce,channel partners and trial teams.”
Sales, Marketing, andDistribution
One of Ventripoint’s primary strategic goals for 2023is to accelerate sales growth. The Company’s sales and marketingefforts continue to focus on the latest generation VMS+ product toleading hospitals and clinics worldwide. Clinicians that haveevaluated the technology see the potential for our products to elevatethe care they provide to their patients and are impressed at how wellVentripoint products provide consistent, reliable, and accuratemeasurements, especially for their most complex cases.
During 2022 Ventripoint investments in sales andmarketing infrastructure included:
-
Key hires of strategic sales leaders to cover theUnited States, Europe, and the United Kingdom.
-
Hires in clinical applications and technical support tosupport its sales team, including direct sales anddistributors.
-
Partnerships with 11 distributors to cover the UnitedStates, Europe, and the United Kingdom; all with a focus in cardiologytherapy bringing the sales team to 33 representatives across the USA,Europe, and the UK.
-
Investing in marketing initiatives to increaseawareness of VMS. One of these major initiatives was attending andsponsoring 12 medical conferences in North America, Europe, and theUnited Kingdom.
Ventripoint’s direct sales teams and distributorshave started out the new year strong and have an aggressive scheduleof booked clinical evaluations for the coming months which are key toclosing sales and increasing reference sites.
About Ventripoint DiagnosticsLtd.
Ventripoint has become anindustry leader in the application of AI (Artificial Intelligence) toechocardiography. Ventripoint's VMS products are powered by itsproprietary KBR technology, which is the result of a decade ofdevelopment and provides accurate volumetric cardiac measurementsequivalent to MRI. This affordable, gold-standard alternative allowscardiologists greater confidence in the management of their patients.Providing better care to patients serves as a springboard and basicstandard for all of Ventripoint's products that guide our future developments. In addition, VMS+ is versatile andcan be used with all ultrasound systems from any vendor supported byregulatory market approvals in the U.S., Europe and Canada.
For further information, pleasecontact:
Jonathan Robinson
416-669-1001
Neither the TSX Venture Exchange nor its RegulationServices Provider (as that term is defined in the policies of the TSXVenture Exchange) accepts responsibility for the adequacy or accuracyof this news release.
Forward Looking Statements
This news release contains forward-looking statementsand forward-looking information within the meaning of applicablesecurities laws. The use of any of the words "expect","anticipate", "continue", "estimate","objective", "ongoing", "may","will", "project", "should","believe", "plans", "intends'' and similarexpressions are intended to identify forward-looking information orstatements. The forward-looking statements and information are basedon certain key expectations and assumptions made by the Company.Although the Company believes that the expectations and assumptions onwhich such forward-looking statements and information are based arereasonable, undue reliance should not be placed on the forward-lookingstatements and information because the Company can give no assurancethat they will prove to be correct.
Since forward-looking statements and informationaddress future events and conditions, by their very nature theyinvolve inherent risks and uncertainties. Actual results could differmaterially from those currently anticipated due to a number of factorsand risks. Factors which could materially affect such forward-lookinginformation are described in the risk factors in the Company's mostrecent annual management's discussion and analysis that is availableon the Company's profile on SEDAR at www.sedar.com. Readers arecautioned that the foregoing list of factors is not exhaustive. Theforward-looking statements included in this news release are expresslyqualified by this cautionary statement. The forward-looking statementsand information contained in this news release are made as of the datehereof and the Company undertakes no obligation to update publicly orrevise any forward-looking statements or information, whether as aresult of new information, future events or otherwise, unless sorequired by applicable securities laws.
Copyright (c) 2023 TheNewswire - All rights reserved.